PAXLOVID™ (PF-07321332; ritonavir) is now authorised in [country]

[A Conditional Marketing Authorisation (CMA) has been granted in the EU for PAXLOVID™ for the treatment of mild-to-moderate Coronavirus Disease 2019 (COVID-19) in adult patients with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing and who are at high risk for progression to severe COVID-19, including hospitalisation or death.]

Ensuring the Authenticity of PAXLOVID™

Authentic PAXLOVID™ from Pfizer Limited will include the Pfizer name on the carton and will be packaged in 5 aluminium push-through blister cards. To ensure that the tablets are legitimate, look for specific text embossed on each side of the tablets. PF-07321332 pink tablets have 3CL embossed on the front and PFE embossed on the back. Ritonavir white tablets have R9 embossed on the front and H embossed on the back.

The outer carton of the box has a colourless, glossy coating that contains a repeated pattern of the Pfizer name and logo all over. The Pfizer name and logo appear in a contrasting matte finish.

If you suspect the PAXLOVID™ you have received may be counterfeit, please report this to your local representative on [telephone number as provided in Package Leaflet]